Wellbutrin (bupropion) vs Lexapro (escitalopram)
Wellbutrin and Lexapro, compared on what the public record actually supports: side effects by rate from each FDA label, what the largest trial comparison found, who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.
the short answer
- is Wellbutrin or Lexapro more effective? in the largest comparison of antidepressant trials (522 trials, 116,477 people, Lancet 2018), both beat placebo on response at about 8 weeks: bupropion odds ratio 1.58 (95% CrI 1.35 to 1.86), escitalopram 1.68 (1.50 to 1.87). in trials that compared them directly, the difference was not statistically distinguishable (odds ratio 1.03, 0.70 to 1.51, low certainty). in the direct trials, the two did about the same on depression scores, and the difference was sexual side effects: in two 8 week trials, orgasm problems at week 8 were reported by 15% on bupropion XL, 30% on escitalopram and 9% on placebo.
- which has fewer side effects? the labels say their trials “cannot be directly compared”, because each drug was tested in different people under different rules. what each label prints: Wellbutrin (bupropion): 9% (300 mg/day); 11% (400 mg/day) stopped for an adverse reaction vs 4% on placebo (Wellbutrin XL label, SPL effective 2026-02-10). Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)). the reactions both labels list, side by side, are in the table below. in the 2018 network, all-cause dropout against placebo was 0.96 for bupropion and 0.90 for escitalopram (directly against each other: 1.23, 0.84 to 1.80).
- which should i take? not a question this page answers. the odds ratios are averages across thousands of strangers; your history, other medications and what you can live with are not in them. the questions for your prescriber below are built from what is on this page.
What this page will not do is rank them. These drugs are in different classes and were tested for partly different things, so a single-axis ranking would be a category error. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →
what the 522-trial comparison found for bupropion and escitalopram
the 2018 Lancet network meta-analysis pooled 522 trials comprising 116 477 participants, the median duration of the acute treatment was 8 weeks (iqr 6–8), and compared 21 antidepressants against placebo and against each other on two outcomes: response (at least a 50% fall on the depression scale) and all-cause dropout, its stand-in for acceptability. odds ratios are against placebo. an odds ratio above 1 on response favours the drug; below 1 on dropout means fewer people stopped than on placebo.
| drug | response vs placebo, OR (95% CrI) | dropout vs placebo, OR (95% CrI) |
|---|---|---|
| Wellbutrin (bupropion) | 1.58 (1.35 to 1.86) | 0.96 (0.81 to 1.14) |
| Lexapro (escitalopram) | 1.68 (1.50 to 1.87) | 0.90 (0.80 to 1.02) |
- bupropion: named in neither the more-effective nor the more-tolerable group of the head-to-head analysis.
- escitalopram: among the drugs that were more effective than other antidepressants in head-to-head trials; among the more tolerable (fewer dropouts) in head-to-head trials.
- directly against each other (the head-to-head network of 194 trials): response odds ratio 1.03 (0.70 to 1.51, low certainty); dropout 1.23 (0.84 to 1.80, moderate certainty). neither interval excludes 1, so the trials did not show a difference between these two. read from the paper's Figure 4 on 2026-10-11.
the other direction, in the authors' words. “the certainty of evidence was moderate to very low”; “The random-effects summary SMD for all antidepressants was 0·30 (95% CrI 0·26–0·34)”, a modest average effect; “positive results need to be taken with great caution, because the trials in this network meta-analysis were of short duration”. 46 (9%) of 522 trials were rated as high risk of bias, 380 (73%) trials as moderate, and 96 (18%) as low. 409 (78%) of 522 studies were funded by pharmaceutical companies. the trials excluded people with psychotic, treatment-resistant or bipolar depression, and the paper says it cannot guide the next choice after a first drug fails. a difference between two odds ratios in the table above is not a difference between the drugs unless the direct comparison shows one.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; doi:10.1016/S0140-6736(17)32802-7. funding of the analysis: National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science. The funder of this study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication. read 2026-10-11 at PMC.
the trials that compared these two directly
who paid: the PubMed record for the 2006 pair of trials carries no funding statement, and we did not confirm the sponsor, so read it as unconfirmed. the 2019 trial in China lists GlaxoSmithKline (China) R&D among its author affiliations. CO-MED was funded by the US National Institute of Mental Health (contract N01 MH-90003). the 2024 heart failure trial declares no conflicts of interest.
- the largest direct comparison is two identical 8 week trials run in 2003 and 2004, 830 adults with moderate to severe depression and normal sexual function at the start: bupropion XL 300 to 450 mg (276 people), escitalopram 10 to 20 mg (281) or placebo (273). pooled, orgasm dysfunction at week 8 was 15% on bupropion XL, 30% on escitalopram and 9% on placebo, and worsened sexual functioning by the end was 20%, 36% and 15%. bupropion was not statistically different from placebo on those measures; escitalopram was.
- the same two trials on depression itself: bupropion XL "did not statistically differ from escitalopram" on Hamilton score change, response or remission. but bupropion XL could not be separated from placebo on the Hamilton score at the .05 level, while escitalopram beat placebo in one of the two trials and in the pooled data. so the pair shows a tolerability difference, not an efficacy one.
- a 2015 to 2016 non-inferiority trial in China (534 people dosed, 8 weeks, no placebo arm) found bupropion XL non-inferior to escitalopram: Hamilton score change of 14.5 against 15.4 points, response 69.6% against 72.9%, remission 39.7% against 47.2%. nausea, the most common adverse event in both groups, was 10.5% on bupropion XL and 18.7% on escitalopram.
- a small trial in 80 people with heart failure and depression symptoms (bupropion 75 mg against escitalopram 5 mg, 12 weeks) found the same improvement on both, with orgasm disorder and sexual dysfunction reported significantly more often on escitalopram.
- taking both together was tested once at scale. CO-MED randomised 665 outpatients with chronic or recurrent depression to escitalopram plus placebo, bupropion plus escitalopram, or venlafaxine plus mirtazapine. remission at 12 weeks was 38.8%, 38.9% and 37.7%, and at 7 months the groups were still not significantly different: "neither medication combination outperformed monotherapy."
limits: the 2006 trials measured sexual function as their primary endpoint, which is the question they were designed to answer; their depression results come with bupropion failing to separate from placebo. the China trial had no placebo arm and lists a company R&D affiliation. the heart failure trial used low doses in 80 people. none of these trials is a reason to start, stop or switch anything; they describe groups, not you, and that conversation belongs with a prescriber.
Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry 2006; doi: 10.4088/jcp.v67n0507. read 2026-10-24.
side effects by rate: what each label prints, not a head-to-head trial
the labels' own warning, first: “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.” the two columns below come from different trials, in different people, under different inclusion rules. read each against its own placebo column, not against the other drug.
| reaction | bupropion SR 300 mg/day (n=376) / bupropion SR 400 mg/day (n=114) vs Placebo (n=385) | Lexapro (N=715) vs Placebo (N=592) |
|---|---|---|
| nausea | 13% / 18% vs 8% | 15% vs 7% |
| dry mouth | 17% / 24% vs 7% | 6% vs 5% |
| diarrhea | 5% / 7% vs 6% | 8% vs 5% |
| constipation | 10% / 5% vs 7% | 3% vs 1% |
| insomnia | 11% / 16% vs 6% | 9% vs 4% |
| somnolence | 2% / 3% vs 2% | 6% vs 2% |
| dizziness | 7% / 11% vs 5% | 5% vs 3% |
| sweating | 6% / 5% vs 2% | 5% vs 2% |
| decreased appetite | 5% / 3% vs 2% | 3% vs 1% |
- Wellbutrin (bupropion): 9% (300 mg/day); 11% (400 mg/day) stopped for an adverse reaction vs 4% on placebo (Wellbutrin XL label, SPL effective 2026-02-10).
- Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)).
what makes each table, in the labels' words
- Wellbutrin XL (bupropion), SPL effective 2026-02-10, 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience, extended-release tablets (Wellbutrin XL); the MDD table below is from trials of the sustained-release (SR) formulation — see caption. inclusion rule: “Table 3 summarizes the adverse reactions that occurred in placebo-controlled trials in patients treated with bupropion HCl sustained-release 300 mg/day and 400 mg/day. These include reactions that occurred in either the 300 mg or 400 mg group at an incidence of 1% or more and were more frequent than in the placebo group.” trials: “Placebo-controlled trials in patients with MDD, bupropion HCl sustained-release 300 mg/day (n=376) and 400 mg/day (n=114) vs placebo (n=385).” DailyMed
- Lexapro (escitalopram), Revised:4/2024 (as printed in the SPL), 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience. inclusion rule: “Reactions included are those occurring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro was greater than the incidence in placebo-treated patients.” trials: “Adverse reactions information for Lexapro was collected from 715 patients with major depressive disorder who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials. Doses ranged from 10 to 20 mg/day; incidences are rounded to the nearest percent by the label itself.” DailyMed
every row above was transcribed from the current FDA label on 2026-09-08; the full tables, including the reactions only one label lists, are on side-effect rates, drug vs placebo. the sexual side-effect rows carry each label's own underreporting caveat on the SSRI sexual side effects page.
bupropion (Wellbutrin)
atypical antidepressant (NDRI)
- FDA approval
- 1985 — immediate-release; marketed from 1989 after a seizure signal, Wellbutrin SR followed in 1996 · full approval journey →
- Who takes it (US, 2024)
- 8,042,018 patients · 34,914,025 prescriptions (AHRQ MEPS)2014 → 2024: 25,051,661 → 34,914,025 prescriptions, up 39%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 8,042,017 people and 34,895,515 prescriptions for 2024; the file gives 8,042,018 and 34,914,025.
- Who pays (2024)
- Medicare: 9,811,789 claims · 2,224,023 beneficiariesMedicaid: ≥6,860,093 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →152,137 all-time reports; most-reported terms: drug ineffective, nausea, fatigue
- Legal & safety record
- the full litigation & recall record →
escitalopram (Lexapro)
SSRI antidepressant
- FDA approval
- 2002 · full approval journey →
- Who takes it (US, 2024)
- 9,460,411 patients · 41,800,787 prescriptions (AHRQ MEPS)2014 → 2024: 19,639,202 → 41,800,787 prescriptions, up 113%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 9,451,175 people and 41,773,078 prescriptions for 2024; the file gives 9,460,411 and 41,800,787.
- Who pays (2024)
- Medicare: 12,700,559 claims · 2,728,707 beneficiariesMedicaid: ≥6,618,277 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →139,512 all-time reports; most-reported terms: fatigue, nausea, drug ineffective
- Legal & safety record
- the full litigation & recall record →
questions for your prescriber, built from this page
this page does not tell you to start, stop or switch anything. it arms the conversation where that decision belongs. take these in:
- which of Wellbutrin and Lexapro did you have in mind first, and what in my history points that way?
- these two are different classes (atypical antidepressant (NDRI); SSRI antidepressant). what are they each being asked to do for me, and is that use on the label or off it?
- the label lists these reactions above placebo for the one you're suggesting. which of them should i expect in the first weeks, and which would make you want to hear from me the same day?
- how long were the approval trials, and what do we know past that point?
- how will we judge whether it is working, by when, and what is the plan if it isn't?
- if i ever want to come off it, how is that done, and over how long?
- is there a cheaper generic or a formulation that changes the dosing, and does my insurance prefer one of these two?
the longer checklist, for any antidepressant, is questions to ask before starting antidepressants. if you are already on one and it feels like it stopped working, that has its own page.
What the warnings mean, drug by drug
Each explainer reads one drug's current FDA label and the studies in our library, in both directions: the boxed warnings with the label's own numbers, the trials behind the approval and how long they ran, side effects by rate, and the research since.
Questions people search
Is Wellbutrin or Lexapro better?
No honest page can answer that in one line. Head-to-head differences between comparable psychiatric medications are usually smaller than rankings suggest, and which fits you depends on your history, other medications, and side-effect trade-offs, a prescriber conversation. What can be compared is the public record (usage, payers, label warnings, approval history, litigation), which is what this page does, with sources.
Is Wellbutrin the same as bupropion, and Lexapro the same as escitalopram?
Wellbutrin is a brand name for bupropion. Lexapro is a brand name for escitalopram. bupropion is an atypical antidepressant (NDRI); escitalopram is a SSRI antidepressant. This page uses the generic names because the federal datasets do.
Which has fewer side effects, Wellbutrin or Lexapro?
The two FDA labels cannot be compared head to head, in their own words, because each drug's trials ran in different people under different rules. What each label prints: Wellbutrin (bupropion): 9% (300 mg/day); 11% (400 mg/day) stopped for an adverse reaction vs 4% on placebo (Wellbutrin XL label, SPL effective 2026-02-10). Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)). The page shows the reactions both labels list, each against its own placebo column. In the 2018 Lancet network meta-analysis, all-cause dropout against placebo was 0.96 for bupropion and 0.90 for escitalopram; directly against each other, 1.23 (0.84 to 1.80), which is not a difference.
Is Wellbutrin or Lexapro more effective for depression?
In the 2018 Lancet network meta-analysis of 522 trials and 116,477 adults with major depressive disorder, both beat placebo on response at about 8 weeks: bupropion odds ratio 1.58 (95% CrI 1.35 to 1.86), escitalopram 1.68 (1.50 to 1.87). In trials that compared them directly the odds ratio was 1.03 (0.70 to 1.51, low certainty), an interval that includes 1, so no difference was shown. In the direct trials, the two did about the same on depression scores, and the difference was sexual side effects: in two 8 week trials, orgasm problems at week 8 were reported by 15% on bupropion XL, 30% on escitalopram and 9% on placebo. The certainty of evidence was moderate to very low, 78% of the trials were industry funded, and the pooled effect of all antidepressants against placebo was a standardised mean difference of 0.30. None of that says which one fits you.
Which is prescribed more, Wellbutrin or Lexapro?
The page shows federal survey estimates we compute from AHRQ’s Medical Expenditure Panel Survey public-use files for both bupropion and escitalopram: patients and prescriptions in the latest reliable year, and the yearly series from 2014 where AHRQ’s reliability rule allows it, with a direction stated only when the change is larger than the survey’s margin of error. Prescription volume reflects habits, prices, and marketing as much as evidence, so it is context, not a verdict.
Where these numbers come from
- Patients and prescriptions: computed by us from AHRQ's public-use Medical Expenditure Panel Survey Prescribed Medicines files, 2014 (HC-168A) to 2024 (HC-254A), with AHRQ's reliability rule (a year with fewer than 60 respondents or a relative standard error over 50% is not shown) — counts of people filling prescriptions, not outcomes. A direction is stated only when the change is larger than the survey's margin of error. Until 29 September 2026 these came from ClinCalc DrugStats, a third-party site; see the correction under each drug where a figure changed.
- Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
- Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
- FAERS: openFDA — reports, never rates; the caveat travels above every count.
- Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.
Explore both drugs in depth: /m/bupropion · /m/escitalopram · or the whole library →